A range of medications are available to help treat lupus nephritis (LN), each offering a specific role in managing the ...

The Lupus Foundation of America (LFA) is proud to honor two exceptional lupus researchers at the 2024 Evelyn V. Hess ...

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care ...

Researchers from Johns Hopkins Medicine and Yale University have collaborated on the development and application of a ...

The Lupus Research Alliance (LRA) is excited to announce the first-ever recipients of the Translational Bridge Award (TBA), ...

Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...

Dr Askanase notes the excitement building around ACR 2024, with positive phase 3 trial results for obinutuzumab in lupus nephritis and dapirolizumab in systemic lupus erythematosus. Attendees can ...

Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

Researchers from both Johns Hopkins Medicine and Yale University collaborated on the development and application of a diagnostic model to detect acute interstitial nephritis (AIN) in patients, which c ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued ...